Abstract:Altered energy metabolism is a biochemical fingerprint of cancer cells that represents one of the “hallmarks of cancer”. This metabolic phenotype is characterized by preferential dependence on glycolysis (the process of conversion of glucose into pyruvate followed by lactate production) for energy production in an oxygen-independent manner. Although glycolysis is less efficient than oxidative phosphorylation in the net yield of adenosine triphosphate (ATP), cancer cells adapt to this mathematical disadvantage by increased glucose up-take, which in turn facilitates a higher rate of glycolysis. Apart from providing cellular energy, the metabolic intermediates of glycolysis also play a pivotal role in macromolecular biosynthesis, thus conferring selective advantage to cancer cells under diminished nutrient supply. Accumulating data also indicate that intracellular ATP is a critical determinant of chemoresistance. Under hypoxic conditions where glycolysis remains the predominant energy producing pathway sensitizing cancer cells would require intracellular depletion of ATP by inhibition of glycolysis. Together, the oncogenic regulation of glycolysis and multifaceted roles of glycolytic components underscore the biological significance of tumor glycolysis. Thus targeting glycolysis remains attractive for therapeutic intervention. Several preclinical investigations have indeed demonstrated the effectiveness of this therapeutic approach thereby supporting its scientific rationale. Recent reviews have provided a wealth of information on the biochemical targets of glycolysis and their inhibitors. The objective of this review is to present the most recent research on the cancer-specific role of glycolytic enzymes including their non-glycolytic functions in order to explore the potential for therapeutic opportunities. Further, we discuss the translational potential of emerging drug candidates in light of technical advances in treatment modalities such as image-guided targeted delivery of cancer therapeutics.

Aerobic glycolysis of vascular endothelial cells: a novel perspective in cancer therapy

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy

Tumor glycolysis as a target for cancer therapy: progress and prospects

Metabolic reprogramming and interventions in angiogenesis

Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.

The sweet trap in tumors: aerobic glycolysis and potential targets for therapy

The Warburg Effect and Its Cancer Therapeutic Implications

Therapeutic Targeting of Cancer Cell Metabolism

Anticancer based on glycolysis pathway in tumor cells

Glycolytic Pathway As A Target For Tumor Inhibition

Advances in the Study of Aerobic Glycolytic Effects in Resistance to Radiotherapy in Malignant Tumors.

Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications

The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment

Glycolysis inhibition for anticancer treatment

Altered Energy Metabolism in Cancer

The metabolic engine of endothelial cells

Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect

Advances of HIF‐1α/glycolysis axis in non‐small cell lung cancer (Review)